Citations

Clear

623 citation(s) found for "Torres, V".

Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
Горбунова, В. А. , Beck, Thaddeus, Hofheinz, Ralf‐Dieter , García‐Alfonso, Pilar , Nechaeva, Marina , Gracián, Antonio Cubillo, Mangel, László, Deming, Dustin A. , Ramanathan, Ramesh K., Torres, Alison Hewitt, Sullivan, Danielle, Komarnitsky, Philip, Élez, Elena , Berlin, Jordan D.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3543-3543

10.1200/jco.2018.36.15_suppl.3543 Get It

Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert W., Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Straus, David J. , Younes, Anas , Fenton, Keenan , Manley, Thomas, Engley, Gerald, Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay K. , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J. , Connors, Joseph M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7541-7541

10.1200/jco.2018.36.15_suppl.7541 Get It

Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).
Evans, Patrick , Morrow, Phuong K. , Storniolo, Anna Maria , Forero‐Torres, Andres , Poznak, Catherine Van , Merkel, Douglas E., Dees, Elizabeth Claire , Hahn, Olwen, Hoffman, Philip C., Nanda, Rita , O’Donnell, Peter H. , Choudhury, Noura J. , Ingle, James N. , Mayer, Ingrid A. , Fleming, Gini F. , Olopade, Olufunmilayo I. , Cox, Nancy J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1071-1071

10.1200/jco.2018.36.15_suppl.1071 Get It

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Vinayak, Shaveta , Tolaney, Sara M. , Mita, Monica , McCann, Georgia A., Tan, Antoinette R. , Hendrickson, Andrea E. Wahner , Forero‐Torres, Andres , Zarwan, Corrine, Erban, John K. , Dezube, Bruce J., Zhou, Yinghui , Buerstatte, Nathan, Arora, Sujata, Achour, Haroun, Telli, Melinda L. , Schwartzberg, Lee Steven , Anders, Carey K. , Wulf, Gerburg M. , Dillon, Patrick Michael , Lynce, Filipa , Telli, Melinda L

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1011-1011

10.1200/jco.2018.36.15_suppl.1011 Get It

Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease
Torres, Vicente E. , Torres, Vicente E

Mayo Clinic

Nephrology Dialysis Transplantation | September 1, 2018 | Volume: 34 | Issue: 1 | Pages: 30-34

10.1093/ndt/gfy297 | PMID 30312438 Get It

ABSTRACT No treatment until now has directly targeted the mechanisms responsible for the development and growth of cysts in autosomal dominant polycystic kidney disease (ADPKD). Strong rationale and preclinical studies using in vitro and in vivo models justified the launching of two large phase 3 clinical trials of tolvaptan in early and later stages of ADPKD. Their design was based on preliminary studies informing on the pharmacokinetics, pharmacodynamics, short-term safety and self-reported tolerability in patients with ADPKD. Tolvaptan slowed kidney growth in the early stage and estimated glomerular filtration rate decline in early and later stages of the disease. All participants had the opportunity to enroll in open-label extension trials to ascertain long-term safety and efficacy. In a single-center analysis of long-term outcomes, the effect of tolvaptan was sustained and cumulative over time supporting a disease-modifying effect of tolvaptan in ADPKD. In the countries where tolvaptan has been approved by regulatory agencies, patients with rapidly progressive ADPKD should be informed about the option of treatment including possible benefits and risks. If a decision to initiate treatment is made, prescribing physicians should educate the patients on the prevention of aquaresis-related adverse events and should be vigilant in the surveillance and management of the potential tolvaptan hepatotoxicity. Other vasopressin V2 receptor antagonists, possibly without potential hepatotoxicity, alternative strategies targeting vasopressin and combination with other drugs able to enhance the efficacy or reduce the aquaresis associated with tolvaptan, deserve further study.
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease
Edwards, Marie E., Blais, Jaime D., Czerwiec, Frank S., Torres, Vicente E. , Kline, Timothy L. , Torres, Vicente E , Erickson, Bradley J.

Mayo Clinic

Clinical Kidney Journal | July 27, 2018 | Volume: 12 | Issue: 1 | Pages: 71-77

10.1093/ckj/sfy078 | PMID 30746130 Get It

Blood Group (BG) Prevalence In End-Stage (ES) Renal Disease (RD): Relationship To Ristocetin Willebrand Factor (VIII: RWF) And Platelet Survival (PS)
Moore, Beverley A. , Donadio, JamesV., Kazmier, F J, Bowie, Ejw, Torres, V, Fuster, Valentı́n , Moore, B

Mayo Clinic

Thrombosis and Haemostasis | July 26, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652983 Get It

BG 0 patients (pts) have lower risk for cardiovascular-thromboembolic disease than A-AB-B pts, particularly males. This might be related to blood hypocoagulability (lower Factor VIII). We report BG frequencies in our Caucasian renal transplant population divided in two groups, ES reflux nephropathy (RN) and ESRD of other etiologies excluding diabetes mellitus.BG 0 male pts are protected, especially for ESRN. To determine whether this sex dependency could be related to different VIII: RWF levels or PS, VIII:RWF levels (n=82) and 51Cr-labelled PS (n=74) were analyzed in controls according to sex and BG.VIII: RWF is sex independent and lower in BG 0. PS is BG independent and shortened in males. A hypercoagulable State reflected by high VIII: RWF and short PS might explain the increased risk of non-BG 0 males to develop ESRD. Non-BG 0 male pts with RN may be more susceptible to develop progressive RD.
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Edwards, Marie E., Irazabal, María V. , Ofstie, Troy G., Bungum, Lisa A., Metzger, Andrew J., Senum, Sarah R. , Hogan, Marie C. , Kline, Timothy L. , Harris, Peter C. , Czerwiec, Frank S., Torres, Vicente E. , El-Zoghby, Ziad M, Kline, Timothy L , Harris, Peter C , Torres, Vicente E , Senum, Sarah R , Irazabal, Maria V , Chebib, Fouad T. , Zoghby, Ziad , Hogan, Marie C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 19, 2018 | Volume: 13 | Issue: 8 | Pages: 1153-1161

10.2215/cjn.01520218 | PMID 30026287 Get It

Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: ( 1 ) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; ( 2 ) Stability of eGFR slopes with duration of follow-up; and ( 3 ) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD, −2.20±2.18 ml/min per 1.73 m 2 per year) and from month 1 (mean±SD, −1.97±2.44 ml/min per 1.73 m 2 per year) compared with controls (mean±SD, −3.50±2.09 ml/min per 1.73 m 2 per year; P <0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.
FP047POTENTIAL IMPACT OF TOLVAPTAN ON BLOOD PRESSURE IN THE TEMPO 3:4 PATIENT POPULATION
Chapman, Arlene B., Devusyt, Oliveir, Gansevoort, Ron T. , Perrone, R. D., Czerwiec, Frank S., Pao, Christina , Torres, Vicente E.

Mayo Clinic

Nephrology Dialysis Transplantation | May 18, 2018 | Volume: 33 | Issue: suppl_1 | Pages: i63-i63

10.1093/ndt/gfy104.fp047 Get It